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Abstract
Background In long-term survivors of osteosarcoma and
Ewing sarcoma treated with the addition of radio- and
chemotherapy, low bone mineral density (BMD) and
fractures have been observed, presumably resulting from
these adjuvants. Because patients with chondrosarcoma
usually are not treated with conventional adjuvant treat-
ment, observation of low BMD in patients with
chondrosarcoma presumably would be the result of other
mechanisms. However, BMD in patients with a history of
chondrosarcoma has not been well characterized.
Questions/Purposes The aim of our study was to address
the following questions: (1) Do long-term survivors of
chondrosarcoma have normal BMD and, if not, which
factors contribute to low BMD? (2) Is there a greater risk of
fracture and does the Fracture Risk Assessment Tool
(FRAX1) score reflect fracture likelihood?
Methods All known patients with a history of chon-
drosarcoma treated at our institution before 2006 were
identified. Of 127 patients believed to be alive at the time
of this study, 30 agreed to participate in this study (11
females, 19 males; mean age at surgery, 39 ± 12 years;
mean followup, 12 ± 5 years). With the data available, the
30 participants were not different from the 97 nonpartici-
pants in terms of age, sex, BMI, tumor grade, tumor
location (axial versus appendicular, lower extremity versus
elsewhere), and use of any treatment known to influence
osteopenia (chemotherapy, lower extremity surgery). BMD
was measured and history of fractures was assessed using a
questionnaire. The patients´ BMD measurements in this
study were sex- and age-matched with a normative sex-
and age-categorized reference population reported by
Kudlacek et al. Associations were tested by univariate
regressions and ANOVAs of all measures of BMD and
eligible oncologic and demographic factors.
Results Eighteen of 30 (60%) patients had a pathologic
BMD according to the WHO dual-energy x-ray absorp-
tiometry definition, 15 (50%) had osteopenia, and three
(10%) had osteoporosis. T-scores in the study cohort were
lower than reference values for the femur neck (mean
difference, 0.64; 95% CI, 0.27–1.01; p\ 0.0015), but not
for the spine (mean difference, 0.39; 95% CI, 0.06 to
0.84; p = 0.09). Thirteen patients (45%) reported a history
of fractures not distinguishing between low and high
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impact. The incidence of fractures was 2.8 greater than
expected from a comparison with a published microcensus
survey of the Austrian population. No effect of the FRAX1
score on fracture risk could be identified (p = 0.057).
Conclusions Long-term survivors of chondrosarcoma
appear to be at greater risk for having lowBMDdevelop than
the healthy population. Although these results are prelimi-
nary and based on a very small sampling of patients, if they
can be confirmed in larger studies, BMD assessment by dual-
energy x-ray absorptiometry might be considered as these
patients are followed posttreatment by sarcoma care units.
The reasons for low BMD still must be elucidated.
Level of Evidence Level IV, prognostic study.
Introduction
Patients with solitary chondrosarcomas, the second most
common primary malignant bone tumor, are treated pri-
marily by surgical resection because of lack of response to
conventional radio- and chemotherapy [37]. Chemotherapy
almost never is used in patients with chondrosarcoma, and
radiation rarely is used, other than in patients with tumor
recurrence or with marginal resection borders. By contrast,
primary malignant bone tumors, including osteosarcoma
and Ewing sarcoma, are treated using wide resection and
(neo)adjuvant chemotherapy. Despite the advantages of
chemo- and radiotherapy to patients’ survival, there is
growing knowledge of side effects, including osteotoxic
ones [2, 13, 15, 23, 34]. Low bone mineral density (BMD)
has been observed in survivors of leukemia [1, 11],
osteosarcoma [15, 34], and Ewing sarcoma [13, 34] after
receiving chemotherapy. Decreased BMD in patients with
bone sarcomas seems to be multifactorial in its genesis, and
potential factors other than chemotherapy such as surgical
treatment of patients, partial weightbearing periods, and
long rehabilitation may contribute to low BMD in patients
with bone sarcomas.
Less is known about chondrosarcoma and BMD.
Patients with chondrosarcoma usually are not treated with
adjuvant treatments, therefore if patients with chondrosar-
coma are at risk of having low BMD develop, which to our
knowledge has not been studied, this presumably would be
the result of other mechanisms. Furthermore, pathologic
fractures can occur at the time of presentation [6, 43] in
chondrosarcomas in approximately 17% to 18% of patients
[7, 36], but it is not known whether fracture risk is greater
in patients with chondrosarcoma than in the healthy pop-
ulation, or whether that risk might be attributable to low
BMD in patients with chondrosarcoma.
The aim of our study was to address the following
questions: (1) Do long-term survivors of chondrosarcoma
maintain normal BMD and, if not, which factors contribute
to low BMD? (2) Is there a greater risk of fractures and
does the Fracture Risk Assessment Tool (FRAX1) [18]
score reflect fracture likelihood?
Patients and Methods
Between 1971 and 2006, 249 patients with chondrosarco-
mas at different locations received a diagnosis and were
treated at our department. One hundred eleven of these
patients already had died of disease at the time of our
study. Eleven patients had received chemotherapy for dif-
ferent reasons and therefore were excluded from this study.
The study was approved by the institutional review board
(EK 373/2009) and conducted according to the Helsinki
Declaration. Informed consent was obtained from all par-
ticipants before inclusion in the study.
Of the 127 patients who were informed by mail, 30 agreed
to participate and were included in the study. This group
consisted of 19 men and 11 women with a mean age of
39 years (SD, 12; range, 17–69 years) at the time of surgery
and mean followup of 12 years (SD, 5; range, 5–24 years). A
questionnaire was used to obtain demographic and clinical
data. Oncologic data were taken from the prospective local
tumor registry and supplemented by thorough chart reviews.
Tumors were histologically graded as G1 to G3 by experi-
enced bone pathologists (MS-K, IA, SL) at our institution.
Grade G1 tumors were seen in 19 (63%) patients, G2 in eight
(27%), and G3 in three (10%). The differentiation of a G1
chondrosarcoma was done when at least all four criteria
(cellularity, matrix changes, binuclearity, and nuclear atypia)
were fulfilled. The pathology reports from the treatment of
these 30 patients were used in this study.
With the data available, the 30 participants were not
different from the 97 nonparticipants, who were lost to
followup, in terms of age, sex, BMI, tumor grade, tumor
location (axial versus appendicular), and use of any treat-
ment known to influence bone health (lower extremity
surgery). In the nonparticipants, there were more lower
extremity tumors versus tumors elsewhere (Table 1).
All patients had surgery at our institution. The common
surgical approach of limb salvage was an excision or
resection of the tumor with or without reconstruction by
using a mega-endoprosthesis. Nineteen patients (63%)
either had excisions or resections only, seven (23%)
received an endoprosthetic reconstruction after resection of
the tumor (Kotz Modular Femoral Tibial Replacement
[KMFTR1]; Stryker Orthopaedics, Mahwah, NJ, USA),
and four (14%) had an amputation. Resection margins were
intralesional in 10 patients, marginal in one, and wide in
19. Tumors were located in the proximal humerus (n = 5),
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proximal femur (n = 2), distal femur (n = 2), pelvis
(n = 4), tibia or fibula (n = 4), scapula (n = 1), rib cage
(n = 5), spine (n = 2), and long finger bones (n = 5).
Densitometric Technique
BMD of the lumbar spine (L1–L4) and of the proximal
femur (total femur, femoral neck) of the nonoperated side
was assessed by dual-energy x-ray absorptiometry (DEXA)
(Hologic DiscoveryTM A, Hologic ExplorerTM; Hologic
Inc, Bedford, MA, USA) (S/N 45313; Lunar1 Prodigy; GE
Medical Systems, Munich, Germany). BMD results are
expressed in terms of SD from a reference population (T-
scores) and from a healthy, age- and sex-matched reference
population (Z-score). To correct for the different facilities,
BMD values were calculated for Lunar1 Medical Systems
according to Genant et al. [9]. Patients were classified
according to the WHO guidelines [35] in three groups:
BMD values greater than 1 were considered normal,
between 1 and 2.5 were classified as osteopenic, and
less than 2.5 were considered osteoporotic [22].
An online fracture risk assessment tool [18] was used to
calculate the FRAX1 [21].
Table 1. Demographics of survivors with chondrosarcoma according to their DEXA-derived bone mineral density





(n = 12) (n = 15) (n = 3) (n = 30) (n = 97)
Demographic
Sex (F/M) 5/7 5/10 1/2 11/19 41/56 0.67
Age (at time of surgery) 34 ± 9 41 ± 13 47 ± 21 39 ± 13 40 (10–86) 0.67
Age (at time of DEXA) 46 ± 11 52 ± 13 57 ± 19 51 ± 13
Followup 14 ± 6 12 ± 5 11 ± 3 13 ± 5
BMI (kg/m2) 27 ± 4 26 ± 5 23 ± 2 26.2 ± 5 25.7 (17–35) 0.74
Physical functioning (SF-36) 66 ± 33 58 ± 34 77 ± 20 63 ± 32 0.6
Tumor grade (available for 88 patients; missing for 9 patients)
G1 9 7 3 19 46 0.39
G2 2 6 0 8 29 1.0
G3 1 2 0 3 13 0.75
Metastasis 0 1 0 1
Local recurrence 2 1 0 3
Localization of tumor (97 patients)
Tibia/fibula 2 2 0 4 10 0.73
Femur 1 2 1 4 23 0.3
Pelvis 1 3 0 4 21 0.43
Scapula 2 0 0 2 3 1.0
Humerus 3 2 0 5 10 0.34
Finger 1 2 2 5 23 0.64
Ribcage 1 3 0 4 6 0.12
Spine 1 1 0 2 1 0.13
Axial 6 31 0.25
Appendicular (extremities, scapula, and pelvis) 24 66 0.25
Lower extremity 12 61 0.03
Elsewhere 18 35 0.03
Surgical method
Curettage 5 4 2 11 27 0.37
Resection 4 4 0 8 34 0.5
Endoprosthetic reconstruction 3 4 0 7 29 0.64
Amputation 0 3 1 4 7 0.28
Lower extremity surgery 12 61 0.03
Ranges are presented in parentheses;  mean in years; mean; DEXA = dual-energy x-ray absorptiometry; all patients were Caucasian and were
free of diabetes, obesity, or other metabolic disorders other than oncologic disease.
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Laboratory Examination
Routine standard laboratory parameters like blood cell
counts, electrolytes including serum calcium and phos-
phate, and bone turnover markers like osteocalcin, bone-
specific alkaline phosphatase, parathyroid hormone, N-
terminal propeptide of type I collagen, and the crosslinked
C-telopeptides of type I collagen, calcitonin, thyroid, and
sexual hormones were assessed for all 30 patients.
Physical Function
All 30 patients had a physical examination and were
evaluated according to Enneking et al. [8]. Physical ability
was measured by Medical Outcomes Study SF-36 physical
functioning subscale [5, 19]. The validity and reliability of
the SF-36 has been established in patients with a history of
cancer [3, 33].
Normative Data
We used a published age-, sex-, and area-of-living matched
control group for bone status [24]. The patients´ BMD
measurements in our study were sex- and age-matched and
compared by paired t-tests [24]. In addition, the incidence
of osteopenia in our study population was compared with
incidences reported in other studies (Table 2) [10, 29]. In
our most prominent age group of patients (40–49 years),
the incidence of osteopenia in men and women was 50%,
whereas according to selected normative data 29% of 31%
had osteopenia [27].
Statistics
The patients´ BMD measurements in our study were sex-
and age-matched with normative sex- and age-categorized
data [24] and compared by paired t-tests. Univariate
regressions of all measures of BMD on BMI, age at diag-
nosis, age at followup, and period between diagnosis and
followup were performed. Correlation between fracture
risk and T-scores was analyzed by logistic regression
models. One-way ANOVA t-tests of all measures of BMD
on sex, surgery, tumor grading, resection margins, and
fractures were performed. The T-score depending on the
FRAX1 was strongly right skewed, therefore this variable
was transformed by taking the square root to obtain a more
symmetric distribution and improve model fit. Owing to the
explorative nature of the study, no correction for multiple
hypothesis testing was done. All statistical calculations
were performed with R 2.15.2 under R-studio (The R
Project for Statistical Computing, Vienna, Austria).
Results
Bone Mineral Density
Overall 18 (60%) of the patients showed low BMD values.
Three patients (10%; one female, two males) had osteo-
porosis, 15 (50%; five females, 10 males) had osteopenia,
and 12 (40%; five females, seven males) had normal BMD
(Table 3). T-scores in the study cohort were less than those of
age- and sex-matched reference values for the femoral neck
(mean difference, 0.64; 95% CI, 0.27–1.01; p = 0.0015), but
not for the spine (mean difference, 0.39; 95% CI, 0.06 to
0.84; p = 0.09). Patients with higher BMI had higher T-
scores of the lumbar spine (0.101; 95% CI, 0.01–0.19;
p = 0.031), but not of the femoral neck (0.02; 95% CI,
0.07 to 0.12; p = 0.61) Age at diagnosis (0.04; 95%CI, –
0.07 to –0.01; p = 0.007) and age at followup (0.37; 95%
CI, 0.07 to  0.01; p = 0.013) showed negative correla-
tions with the T-score of the femoral neck. However, no
correlation of T-scores of the lumbar spine was identified for
age at diagnosis and for age at followup. The followup per-
iod, type of surgery, and physical ability/activity (SF-36
physical functioning) were not associated with T-scores of
the femoral neck nor the lumbar spine. Physical ability in
Table 2. Comparison of the prevalence of osteopenia
Study Age groups (range in years)
20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69
Current study 50% 25% 50% 75% 71%
Looker et al. (NHANES III) [29] NA NA NA NA NA NA 34%–49%
Looker et al. (NHANES 2005–2006) [29] NA NA NA NA NA NA 32%–50%
Guzma´n Ibarra et al.* [10] NA NA NA NA NA 18% 47% 44% 64% 53%
Larjiani et al.** [27] 13%–17% 8%–24% 29%–31% 42%––46% 47%–50%
* Data presented for womens´ incidence of osteopenia; **data presented as lowest and highest value of womens´ and mens´osteopenia in femur
neck and spine; NA = not available.
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patients who had surgery of the upper limb (77 ± 27)
compared with the lower limb (60 ± 27) showed no sub-
stantial difference (mean difference, 17; 95% CI, 10 to 45;
p = 0.21). In addition, T-scores of the femoral neck in
patients who had upper limb surgery (0.99 ± 1.1) and
lower limb surgery (1.5 ± 0.78) showed no difference
(mean difference, 0.5; 95% CI, 1.4 to 0.5; p = 0.27).
Fracture Risk
Thirteen patients reported a history of fractures (45%).
Throughout the study population, the incidence of fractures
per year was 0.034. In comparison, incidence rates in the
Austrian reference population range between 0.010 and
0.018 fractures per year in the corresponding sex-specific
age groups [41]. In an age and sex-matched sample from the
population, a total of 4.7 fractures would be expected when
accounting for the followup period for each patient. Frac-
tures in the study population were not localized at typical
osteoporotic fragility fracture sites (Table 4). BMD
expressed by T-scores of the femoral neck (odds ratio [OR],
0.59; 95% CI, 0.25–1.21; p = 0.181) and lumbar spine (OR,
0.86; 95% CI, 0.44–1.62; p = 0.64) did not show effects on
the incidence of fractures. The FRAX1 score did not show
effects on the incidence of fractures (OR, 2.5; 95% CI,
0.97–6.54; p = 0.057). No substantial difference in SF-36
physical function score was seen between patients with
fractures (60 ± 31) and those with no fractures (66 ± 33)
(mean difference, 6; 95% CI, 19.11 to 31.78; p = 0.61).
Discussion
Chondrosarcoma is the secondmost-frequent malignant bone
tumor. The standard treatment of patients with chondrosar-
coma is a wide resection or aggressive curettage for selected
low-grade extremity chondrosarcomas only. Although other
primarymalignant bone tumors like osteosarcoma and Ewing
sarcoma are treated with a multidisciplinary approach
including chemotherapy and surgical resection, patients with
chondrosarcoma do not show any clinical response to con-
ventional adjuvant treatments. Low BMD and increased
fracture rates after multimodal treatment of chemosensitive
primary bone tumors are presumed to be osteotoxic side
effects of chemotherapeutic treatments [2, 13, 15, 23]; how-
ever, other risk factors for lowBMD in patients with a history
of bone tumors may be present. To test the BMD of patients
with chondrosarcoma, and because treatment of osteoporosis
and osteopenia may be indicated once it is discovered, we
wanted to assess whether patients with chondrosarcoma
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This study is limited because of the patients assumed to
be alive, only 25% responded and agreed to participate.
Survivors of malignant diseases may decline participation
in studies for various reasons including general rejection of
study participation or owing to professional commitments,
not having time for followups, or relocation of residence.
This poses a selection bias. However, because our tumor
register’s demographic and oncologic data for the 97
patients lost to followup, including age, sex, BMI, tumor
grade, tumor location (axial versus appendicular), and use
of any treatment that could influence osteopenia (eg,
chemotherapy), did not differ from the data of our study
patients (Table 1), we believe our study patients reasonably
represent the population of patients with this condition.
However, there were more lower extremity tumors in the
97 nonparticipants, therefore you could argue that, if less
mobility plays a role after treatment of lower extremity
tumors, which potentially could lead to less BMD, then the
nonparticipants would be even more prone to low BMD,
and results would be even more powerful.
The tumors varied in size and by site with some lower
extremity and some upper extremity lesions. In addition
patients had many different types of surgical procedures,
which potentially could affect BMD findings. With the small
numbers available, we could not show that these issues were
statistically related to BMD, but a study of larger groups of
patients might show differences. Our patient population
includes patients of differing ages, and with low- and high-
grade tumors, major resections/reconstructions, and curet-
tage. Our numbers are not large enough to look at differences
between a high-grade chondrosarcoma of the lower extrem-
ity treated with megaprostheses and a small chondrosarcoma
of the finger. Additional study is needed with a larger, more
homogeneous population of patients before our findings can
be generalized. Finally, our numbers are too small to perform
a multivariate analysis to assess which are the most important
factors predicting low BMD in the patients with chon-
drosarcoma; as such, confounding variables may have
influenced some of our findings. No-difference findings
could be a function of insufficient sample size.
Eighteen (60%) of 30 patients in our study had a patho-
logic BMD. T-scores in the study cohort were lower than
reference values for the femoral neck (p\ 0.001), but not for
the spine (p = 0.11). Osteoporosis was seen in four patients.
Surgical treatment of patients with bone sarcoma is followed
by a long rehabilitation and periods with partial weight-
bearing. Patients often are restricted in their activities of daily
living [32], physical activity [14], and sports activity [12, 25],
which may influence BMD because of inactivity [17, 26, 28,
30]. Furthermore, in patients with chondrosarcoma, patho-
logic fractures occur at presentation of the disease [6, 43] in
approximately 17% to 18% [6] and it is not known whether
these patients continue to experience bone events once a
chondrosarcoma has been diagnosed. Unlike patients with
bone tumors which are treated with chemotherapy and
radiation and are known to affect bone density [13, 15, 38],
patients with chondrosarcoma generally do not receive these
adjuvant treatments. Therefore, the reason for the lower-
than-expected BMDs in patients with chondrosarcoma is not
known However, abnormally low BMD in our patients was
surprisingly common (60%; 18 of 30), and we did not detect
any particular predictors of this apart from BMI, which
exerted a protective effect. Morin et al. [31] discussed weight
and bodymass predicting low BMD in women 40 to 59 years
old. In line with these data, the most powerful factor indi-
cating low Z-scores of the femoral neck in our study was
BMI. However, this appears to be an associated factor in
patients with postmenopausal osteoporosis and in patients
with a history of chemosensitive malignant bone tumors [13,
38, 40]. Although these long-term data did not reveal a
correlation between sex hormones and bone status at the time
of followup, there is some evidence that estrogen metabolism
may be associated with the occurrence of chondrosarcoma
and translational research has validated estrogen signaling a
potential antitumor-therapeutic target [7]. Because sex hor-
mones are involved in bone homeostasis as well, there could
Table 4. Fractures in survivors of chondrosarcoma
Variable Number of fractures (males/females)
Normal BMD Osteopenia Osteoporosis Total
4 (4/0) 6 (3/3) 3 (2/1) 13 (9/4)
FRAX1 score (calculation included BMD) 0.7 (0–2) 3.9 (1–11) 6.7 (4–8) 3.5 (0–11)
Location of fracture
Hand (carpus, phalanges) 2 (2/0) 2 (1/1) 4 (4/1)
Distal radius 2 (0/2) 2 (0/2)
Humerus 1 (0/1) 1 (0/1)
Tibia 1 (1/0) 2 (2/0) 1 (1/0) 4 (4/0)
Femur 1 (1/0) 1 (1/0) 1 (1/0)
FRAX1 = Fracture Risk Assessment Tool; BMD = bone mineral density.
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be a possible link. Another possibility is that the BMD
findings may be ‘‘tumor-induced,’’ that is, related to a factor
produced by the tumor, which is seen in certain types of
tumors such as myeloma [42]. In these patients bone loss is
mediated by various biologic factors produced by osteoblasts
or by malignant plasma cells [42]. Tumor-induced bone loss
also is seen with metastatic disease [4]. Future studies will
need to determine whether there is any such tumor-related
factor produced by chondrosarcoma cells.
A total of 45% of our patients (13 of 30) experienced
fractures, and these fractures did not occur at typical
osteoporotic fragility fracture sites. Two low-impact radius
fractures were reported; the others may be considered high-
impact fractures The incidence of fractures in our study
population was higher than expected by a factor of 2.8
compared with a microcensus survey of the Austrian
population [41]. Low BMD has been shown to be a good
predictor for fractures in the elderly [20, 39]. Our study did
not reveal an effect of low BMD on fractures in patients
with a history of chondrosarcoma. There might be other
reasons for fractures than low BMD, such as changes of the
cortical bone, that cannot be assessed by DEXA [16]. In
addition, no correlation between FRAX1 score and frac-
ture risk was identified.
Our study showed an abnormal BMD in the majority of
patients with chondrosarcoma. Patients with a history of
chondrosarcoma appear to have low BMD of the proximal
femur develop for reasons yet unknown and might have
higher fracture rates than healthy age-related persons. The
no-difference findings concerning low BMD in this series
regarding age, different surgical techniques, tumor sites, and
followup may be the result of insufficient sample size;
alternatively, they may represent a yet-to-be defined tumor-
related effect associated with chondrosarcoma, as seen in
certain other tumors [4, 42]. As a consequence, physicians
should be aware of the potential for low BMD in patients
with chondrosarcoma and should consider evaluation and
possible treatment of those with low BMD. Additional
studies with larger numbers of patients with chondrosarcoma
are necessary to confirm our findings, but our study may
serve as a pilot study to further investigate the hypotheses of
possible tumor-related bone loss in patients with sarcomas.
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